CBClaudia Benedetti

Claudia Benedetti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Claudia Benedetti has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment of Safety and Efficacy of Expanded Hemodialysis with Medium Cut-Off Dialyzer Compared to Haemodiafiltration

    by Matteo Marcello, Marco Simonini, Anna Lorenzin, Valentina Corradi, Grazia Maria Virzì, Carlotta Caprara, Alessandra Brendolan, Claudia Benedetti, Paolo Lentini, Monica Zanella, et al.

    Background: Removal of large uraemic toxins is still a challenge. Haemodiafiltration (HDF) has produced some results, although large convective volume, optimal vascular access to increase the blood flow rate and strict water quality management are required. Medium cut-off, high-retention-onset membranes have been recently developed, introducing the concept therapy called expanded haemodialysis (HDx). Furthermore, vitamin E-coated membrane has potential beneficial effects on inflammation and oxidative stress. Methods: A prospective longitudinal multicentre study was conducted for 3 months among 24 chronic haemodialysis patients. Patients were randomly assigned into either HDF with high-flux membrane or HDx with Theranova or ViE-X membrane. The primary goal was to assess albumin loss among the three types of dialyzers. Secondary goals included assessment of depurative efficacy for uraemic toxins and clinical outcomes. Results: Mean albumin loss was significantly higher in patients undergoing HDx with Theranova membrane, without any difference in serum albumin concentration among the three groups. Instantaneous clearance of small and middle molecules was significantly higher in patients undergoing HDF, but we did not find differences in removal ratio and Kt/V. Reduction in the erythropoietin resistance index was observed in patients treated with ViE-X membrane due to their lower dialysis vintage. Conclusions: The higher albumin loss during HDx has no effects on pre-dialysis serum albumin. HDx with Theranova in the presence of lower session length, lower Qb, lower convective dose, and lower instantaneous clearance reached the same dialysis efficacy compared to HDF.


  • Open Access

    Assessment of Safety and Efficacy of Expanded Hemodialysis with Medium Cut-Off Dialyzer Compared to Hemodiafiltration

    by Matteo Marcello, Marco Simonini, Anna Lorenzin, Valentina Corradi, Grazia Maria Virzì, Carlotta Caprara, Alessandra Brendolan, Claudia Benedetti, Paolo Lentini, Monica Zanella, et al.

    Background: Removal of large uraemic toxins is still a challenge. HDF has produced some results although large convective volume, optimal vascular access to increase the blood flow rate and strict water quality management are required. Medium Cut-Off, high Retention Onset membrane have been recently developed introducing the concept therapy called “expanded haemodialysis” (HDx). Furthermore, vitamin E-coated membrane has potential beneficial effects on inflammation and oxidative stress. Ma-terial and Methods: A prospective longitudinal multi-center study was conducted for 3 months among 24 chronic haemodialysis patients. Patients were randomly assigned into either HDF with high flux membrane or HDx with Theranova or ViE-X mem-brane. The primary goal was to assess albumin loss among the three types of dialyzers. Secondary goals included assessment of depurative efficacy for uraemic toxins and clinical outcomes. Results: Mean albumin loss was significantly higher in patients undergoing HDx with Theranova membrane (ANOVA, p< 0.001) without any differ-ence in serum albumin concentration among the three groups. Instantaneous clearance of small and middle molecules was significantly higher in patients undergoing HDF, but we didn’t find differences in removal ratio and Kt/V. Reduction of Erythropoietin resistance index was observed in patients treated with ViE-X membrane due to their lower dialysis vintage. Conclusion: The higher albumin loss during HDx has no effects on pre-dialysis serum albumin. HDx with Theranova® in presence of lower session length, lower Qb , lower convective dose and lower instantaneous clearance reached same dialysis efficacy compared to HDF.


  • Open Access

    The Vascular Disease of Diabetic Kidney Disease

    by Paolo Lentini, Luca Zanoli, Claudio Ronco, Claudia Benedetti, Antonino Previti, Giorgio Laudadio, Federica Vienna, Sofia Andrighetto, Valeria Fuso, Giovanni Gambaro

    Background: The incidence of cardiovascular disease (CVD) is increased in patients with diabetic kidney disease (DKD). Summary: Aortic stiffness is a well-accepted biomarker for cardiovascular (CV) events in all stages of CKD. The worldwide prevalence of diabetes continues to grow, as does the prevalence of DKD. Insulin resistance, hyperglycaemia, hypertension, and the metabolic abnormalities of type-2 diabetes are all involved in the pathogenesis of CVD. The effect of these toxins on cardiac and vascular function is amplified by the worsening of renal function and the parallel rise of uraemic toxins. Key Messages: In this narrative review, we analysed why arterial stiffening can be considered a vascular mediator between diabetes and cardiac dysfunction, and we discussed the strong CV and nephroprotective effects of sodium-glucose cotransporter type-2 inhibitors.


  • Open Access

    Evidence of potent humoral immune activity in COVID-19-infected kidney transplant recipients

    by Susan Hartzell, Sofia Bin, Claudia Benedetti, Meredith Haverly, Lorenzo Gallon, Gianluigi Zaza, Leonardo V. Riella, Madhav C. Menon, Sander Florman, Adeeb H. Rahman, et al.